Chronic Fatigue Syndrome (ME/CFS) — Symptoms, Diagnosis & Management — Symptoms, Causes & Treatment | MyMedicPlus

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, serious, multisystem disease characterised by profound fatigue that is not relieved by rest, post-exertional malaise (PEM), cognitive dysfunction, sleep disturbances, and orthostatic intolerance. It affects an estimated 17-24 million people globally, predominantly women (3:1 ratio), and can affect people of all ages including children. ME/CFS is classified by the WHO as a neurological condition (ICD-11: 8E49). Long COVID has dramatically increased awareness — an estimated 1-2% of those with COVID-19 develop ME/CFS-like illness, with post-exertional malaise as the defining feature. The 2021 NICE guideline (NG206) marked a pivotal shift in understanding ME/CFS: it removed Graded Exercise Therapy (GET) as a recommended treatment, recognising the biological reality of post-exertional malaise and the potential harm that forced activity escalation causes in people with this condition.

The cause of ME/CFS is not fully understood but is thought to involve an initial trigger (most commonly a viral or infectious illness — Epstein-Barr virus/EBV, SARS-CoV-2, Enterovirus, Coxsackievirus B, Q fever from Coxiella burnetii, Ross River virus) in genetically susceptible individuals, leading to dysregulation of the immune system, autonomic nervous system, energy metabolism, and gut microbiome. Biological hypotheses include: mitochondrial dysfunction (impaired cellular energy production); immune activation and chronic inflammation; HPA axis dysregulation; and SARS-CoV-2 microclot formation in long COVID-ME/CFS. Risk factors: female sex, psychological stress, pre-existing anxiety, previous infections, and genetic susceptibility. Emerging research points to immune dysregulation — particularly natural killer cell dysfunction, elevated pro-inflammatory cytokines, and reactivation of latent herpesviruses (EBV, HHV-6) — as central pathological mechanisms in ME/CFS that are now reproducible across multiple independent international research cohorts.

Post-exertional malaise (PEM) — the hallmark feature: a worsening of all symptoms following physical, cognitive, or emotional exertion that exceeds the person's energy envelope — typically delayed by 12-48 hours. Core symptoms (required for diagnosis per 2015 IOM/NICE 2021 criteria): debilitating fatigue (substantially reduces activity, not improved by rest); PEM (unrefreshing sleep/rest after exertion); cognitive impairment ('brain fog' — difficulty concentrating, memory problems, word-finding difficulties, slowed processing); and orthostatic intolerance (worsening symptoms on standing — palpitations, lightheadedness, POTS). Additional symptoms: widespread pain, headaches, sore throat, tender lymph nodes, temperature dysregulation, sensory hypersensitivity (light, sound, smell). Symptom severity fluctuates significantly from day to day and week to week; the characteristic delayed post-exertional malaise — typically peaking 12-48 hours after physical or cognitive activity — is the defining feature that distinguishes ME/CFS from other fatigue conditions and must be present for a confident diagnosis under all current diagnostic criteria.

ME/CFS is a clinical diagnosis based on internationally recognised diagnostic criteria (2015 IOM criteria, NICE 2021 NG206 guideline). Required features (all must be present for over 6 months, with over 50% of the time): substantial impairment; post-exertional malaise; unrefreshing sleep; cognitive impairment; and either orthostatic intolerance or chronic widespread pain. Exclusion of other diagnoses is required: FBC, ESR/CRP, thyroid function, liver and renal function, glucose, ferritin, B12, folate, serum calcium, and urinalysis. The 2021 NICE guideline removed the requirement to exclude psychological diagnoses first — ME/CFS may coexist with anxiety and depression but these are not causal. Graded Exercise Therapy (GET) and CBT aimed at reversing 'illness beliefs' are no longer recommended as primary treatments (NICE 2021).

Pacing and energy envelope management: the cornerstone of ME/CFS management. Staying within the 'energy envelope' — the available energy for a given day — prevents PEM crashes. Pacing tools: activity diaries, heart rate monitoring (keeping heart rate below anaerobic threshold), resting before symptoms worsen (pre-emptive rest). Sleep management: consistent sleep-wake schedule; stimulus control techniques; avoid lying in bed awake; melatonin for circadian disruption; low-dose amitriptyline or mirtazapine for sleep initiation and muscle pain. Orthostatic intolerance: increased fluid and salt intake; compression stockings; beta-blockers or fludrocortisone for POTS (postural orthostatic tachycardia syndrome). Pain management: low-dose naltrexone (off-label, emerging evidence); pregabalin/gabapentin for neuropathic pain; paracetamol/NSAIDs for headache/musculoskeletal pain. Low-dose naltrexone (LDN) shows promise in ME/CFS clinical trials. Rintatolimod (Ampligen) is available in the USA for severe ME/CFS. No curative treatment currently exists.

Severe ME/CFS can be profoundly disabling — 25-30% of patients are housebound or bedbound at some point in their illness. Inappropriate management — particularly forcing activity beyond the energy envelope (graded exercise therapy as previously recommended) — can cause significant deterioration and prolonged PEM crashes lasting weeks to months. Social isolation, career loss, financial hardship, and relationship breakdown are common consequences of severe ME/CFS. Depression and anxiety frequently develop as secondary conditions in response to illness severity and life disruption. Misdiagnosis or dismissal ('it's all in your head') delays appropriate support and worsens prognosis. ME/CFS has a mortality rate modestly higher than age-matched controls — from suicide and cardiovascular disease.

There is no proven prevention for ME/CFS. Early management of infections (adequate rest during acute illness) may reduce post-infectious ME/CFS risk. For people with confirmed ME/CFS: learn pacing using a personalised energy envelope — keep a diary of activities and symptoms; rest regularly before reaching the limit; plan activities based on the available energy on a given day. Avoid 'boom and bust' cycles (overactivity when feeling well followed by crash). Stay connected socially within energy limits. Seek support from a GP or ME/CFS specialist for symptom management. Join ME/CFS patient support organisations (ME Association, Action for ME). Psychological support (counselling, acceptance-based therapy) to cope with the chronic nature of the illness — not to 'cure' it. Inform employers and schools about the condition to access reasonable adjustments.

See a GP for debilitating fatigue lasting more than 4 weeks that is not explained by other medical causes, especially if accompanied by post-exertional worsening, unrefreshing sleep, or cognitive difficulties ('brain fog'). Request assessment for ME/CFS using the NICE 2021 criteria (NG206) — do not accept dismissal of symptoms. Investigations should exclude other causes: FBC, ESR, TFTs, ferritin, B12, calcium, glucose, LFTs, and urinalysis. Seek urgent attention for: sudden severe worsening of all symptoms after exertion lasting more than 48 hours (severe PEM crash); new neurological symptoms (weakness, numbness, coordination problems); unexplained weight loss; signs of suicidal crisis from the psychological burden of severe ME/CFS. Ask for referral to an ME/CFS specialist clinic — NICE 2021 guidance states referral should be made after 3 months if no recovery is occurring. Avoid graded exercise therapy (GET) if offered as a primary treatment — this is no longer recommended by NICE and may worsen your condition.